These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 22488221)
21. Propranolol treatment lowers blood pressure, reduces vascular inflammatory markers and improves endothelial function in obese mice. da Silva Franco N; Lubaczeuski C; Guizoni DM; Victorio JA; Santos-Silva JC; Brum PC; Carneiro EM; Davel AP Pharmacol Res; 2017 Aug; 122():35-45. PubMed ID: 28539257 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms of hypertension in the cardiometabolic syndrome. Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221 [TBL] [Abstract][Full Text] [Related]
23. The sympathetic nervous system in obesity hypertension. Lohmeier TE; Iliescu R Curr Hypertens Rep; 2013 Aug; 15(4):409-16. PubMed ID: 23677623 [TBL] [Abstract][Full Text] [Related]
24. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Cabandugama PK; Gardner MJ; Sowers JR Med Clin North Am; 2017 Jan; 101(1):129-137. PubMed ID: 27884224 [TBL] [Abstract][Full Text] [Related]
25. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Barton M; Carmona R; Ortmann J; Krieger JE; Traupe T Int J Biochem Cell Biol; 2003 Jun; 35(6):826-37. PubMed ID: 12676169 [TBL] [Abstract][Full Text] [Related]
26. Insulin resistance, hyperinsulinemia and hypertension. Weidmann P; de Courten M; Böhlen L J Hypertens Suppl; 1993 Dec; 11(5):S27-38. PubMed ID: 8158379 [TBL] [Abstract][Full Text] [Related]
27. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369 [TBL] [Abstract][Full Text] [Related]
28. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Manrique C; Lastra G; Gardner M; Sowers JR Med Clin North Am; 2009 May; 93(3):569-82. PubMed ID: 19427492 [TBL] [Abstract][Full Text] [Related]
29. Impact of the obesity epidemic on hypertension and renal disease. Hall JE; Jones DW; Kuo JJ; da Silva A; Tallam LS; Liu J Curr Hypertens Rep; 2003 Oct; 5(5):386-92. PubMed ID: 12948431 [TBL] [Abstract][Full Text] [Related]
30. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Hall JE; Mouton AJ; da Silva AA; Omoto ACM; Wang Z; Li X; do Carmo JM Cardiovasc Res; 2021 Jul; 117(8):1859-1876. PubMed ID: 33258945 [TBL] [Abstract][Full Text] [Related]
31. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. Balasubramanian P; Hall D; Subramanian M Geroscience; 2019 Feb; 41(1):13-24. PubMed ID: 30519806 [TBL] [Abstract][Full Text] [Related]
32. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Engeli S; Sharma AM Curr Opin Cardiol; 2002 Jul; 17(4):355-9. PubMed ID: 12151869 [TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and clinical physiology of hypertension. Singh M; Mensah GA; Bakris G Cardiol Clin; 2010 Nov; 28(4):545-59. PubMed ID: 20937440 [TBL] [Abstract][Full Text] [Related]
34. Is obesity a major cause of chronic kidney disease? Hall JE; Henegar JR; Dwyer TM; Liu J; Da Silva AA; Kuo JJ; Tallam L Adv Ren Replace Ther; 2004 Jan; 11(1):41-54. PubMed ID: 14730537 [TBL] [Abstract][Full Text] [Related]
35. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Sharma AM Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127 [TBL] [Abstract][Full Text] [Related]
36. Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice. Huby AC; Otvos L; Belin de Chantemèle EJ Hypertension; 2016 May; 67(5):1020-8. PubMed ID: 26953321 [TBL] [Abstract][Full Text] [Related]